Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer patients suffering from painful and debilitating skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor therapies—an area of high unmet medical need. "We're seeing encouraging signals from our open-label Phase 2a cohort and are taking bold steps to accelerate availability for patients in need," said Robb Knie, Chief Executive ...